Pfizer CEO says 'no commitments' made in meetings with US government on drug pricing

Pfizer CEO Albert Bourla stated that the company has engaged in preliminary discussions with the Trump administration regarding lowering U.S. drug prices, but no concrete commitments have been made. Bourla expressed hope that U.S. pressure on European countries to increase drug prices could alleviate the need for price controls in the U.S., and suggested Pfizer might consider withdrawing drugs from government reimbursement in certain countries if prices do not rise, instead making them available on the open market.

Analysis

Pfizer's Chief Executive, Albert Bourla, confirmed ongoing, albeit preliminary, discussions with the Trump administration concerning U.S. drug prices, as stated at Goldman Sachs’ Global Healthcare Conference. These meetings, described by Bourla as "cordial" but focused on "high-level ideas" without delving into "any substance yet," have not resulted in any commitments from drug companies. This situation arises in the context of President Donald Trump's recent executive order directing drugmakers to align U.S. medicine prices with those in other developed nations—specifically, the lowest price received in countries with a GDP per capita at least 60% of U.S. per-capita GDP—a policy whose implementation is viewed as difficult by legal experts. Bourla conveyed optimism that U.S. pressure might lead to increased drug prices in European countries, potentially averting stricter U.S. price controls. Critically, should U.S. price controls be enacted without corresponding price increases in Europe, Pfizer would consider withdrawing its drugs from government reimbursement in some international markets, making them available solely on the "open market." This potential strategic shift and the ongoing regulatory uncertainty contribute to the moderately negative sentiment (PFE: -0.4) surrounding the company's future pricing power and profitability.

Key Decisions for Investors

• Investors should closely monitor developments related to U.S. drug pricing regulations and the Trump administration's negotiations with pharmaceutical companies, given the significant potential impact on Pfizer's U.S. revenues.
• Evaluate the potential financial implications of Pfizer's stated strategy to shift drugs to open markets in certain international territories if favorable pricing under reimbursement schemes is not achievable, as this could affect international sales volumes and margins.
• Maintain a cautious stance towards Pfizer, as the ongoing high-level, non-committal discussions on U.S. drug pricing create significant uncertainty regarding the company's future pricing power and profitability in its largest market.